Experts have stated that Olaparib could become a revolutionary treatment for prostate cancer – the first genetically targeted drug for fighting the disease. The precision medicine is already used by the NHS for ovarian cancer and has been called a game-changer by cancer doctors. Findings presented at a recent conference show how in trials, it
AstraZeneca and Takeda have signed a deal to mutually develop and commercialise an experimental therapy for Parkinson’s disease. The companies will work together to advance AZ’ MEDI1341, an antibody to alpha-synuclein, an aggregation-prone protein that contributes to the development of the condition.
Actelion says it is disappointed by the decision made by Scottish cost regulators to refuse NHS funding for pulmonary arterial hypertension drug Uptravi. The Scottish Medicines Consortium (SMC) issued guidance not recommending use of Uptravi (selexipag) for a sub-population of adult patients with the potentially life-threatening condition, which leads to an increase in blood pressure
Patients with severe and uncontrolled asthma found that taking AstraZeneca’s experimental drug benralizumab in a late-stage study either significantly reduced the need or stopped altogether their intake of oral corticosteroids (OCS), the drug was also shown to dramatically cut related hospitalisations.
AstraZeneca has expanded a late-stage trial that assess a potential new immuno-oncology (IO) therapy combination for the first-line treatment of non-small cell lung cancer (NSCLC), to include extra endpoints for both the combo and monotherapy. The Phase III MYSTIC trial was originally designed to assess the benefit of durvalumab monotherapy and a combination of durvalumab
AstraZeneca has launched two new trials with its SGLT-2 inhibitor Forxiga with the aim of exploring its potential beyond the drug’s approved diabetes indication. AZ have initiated two randomised, placebo-controlled Phase IIIb outcome trials assessing Forxiga in the management of chronic kidney disease and chronic heart failure, within participants with and without type-2 diabetes. The
AstraZeneca have confirmed that they remain confident of generating annual sales of over $45 billion by 2023. The increase is expected as a result of accelerating growth momentum from both AstraZeneca’s existing products and those currently awaiting market approval. Five current growth platforms (diabetes, Brilinta, respiratory, Emerging Markets and Japan) currently account for over half
AstraZeneca has announced that they are acquiring tissue sample specialist, Definiens, increasing their oncology efforts. AstraZeneca’s MedImmune unit is paying an initial $150 million, followed by additional predetermined milestone payments, to acquire Definiens. AstraZeneca noted that Definiens has “pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics, which dramatically improves the identification
The day after announcing a partnership with UK’s Horizon Discovery, AstraZeneca have announced another oncology partnership with Immunocore, a UK biotechnology company. The agreement with Immunocore focuses around Immunocore’s ImmTAC technology. The technology has created a platform of biological medicines which direct a patient’s T cells to specifically destroy only cancerous cells, avoiding damage to
AstraZeneca have announced that they have licensed a drug which is currently in mid-stage clinical studies for ovarian cancer from Merck & Co. The agreement revolves around MK-1775, an oral small molecule inhibitor of WEE1 kinase, a cell cycle checkpoint protein regulator. Preclinical results have indicated that disruption of WEE1 may improve the cell killing